Effect of WEB2170 in B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and CASPASE-3 (2006)
- Authors:
- USP affiliated authors: NEGRO, SONIA JANCAR - ICB ; CHAMMAS, ROGER - FM
- Unidades: ICB; FM
- Assunto: IMUNOLOGIA
- Language: Inglês
- Abstract: Introduction & Objectives: phagocytosis of apoptotic cells has been shown to inhibit macrophages activation,favoring tumor growth.We have recently demonstrated that Platelet Activating Factor (PAF) receptor is involved in the phagocytosis of apoptotic cells.The present study investigated the effect of a PAF receptor antagonist,WEB2170,alone or associated with an apoptosis inducer chemotherapeutic agent,Dacarbazine (DCB; 40µg, ip),on melanoma B16F10 growth,survival and on the expression of galectin-3,CD34 and activated caspase-3 (indicating inflammatory influx into the tumor,neoangiogenesis and apoptosis respectively).Methods & Results: an injection of either WEB2170 (5mg/Kg, ip),or its diluent was given ip in C57/BL6 mice (5 animals/group).After 30 minutes of the treatment start,mice were subcutaneously injected with B16F10 melanoma cells.To evaluate the combination of WEB2170 with DCB,the animals received ip cycles of DCB on each 3 days,in addition to WEB2170 treatment.Expression of galectin-3,CD34 and capase-3 in the solid tumor was evaluated through immunohistochemistry staining of tumor mass sections 10 days after tumor implantation.Treatment with WEB2170 alone reduced the size of the tumor but had no effect on survival time.Association WEB+DCB reduced tumor size and improved survival time compared to WEB treatment alone (35 and 24 days respectively).Preliminary data indicate that galectin-3 and CD34 expression and thevascular area were not affected by treatments but the number of capillaries in the tumor mass was reduced by WEB2170 and WEB+DCB (34.6 ± 3.1 in nontreated versus 22.8 ± 1.4 and 26.0 ± 1.7 respectively).WEB2170 inhibited active caspase-3 expression only in mice treated with DCB (0.30 ± 0.02 versus 0.19 ± 0.02).Conclusion: a PAF receptor antagonist in association with DCB inhibits melanoma B16F10 growth.
- Imprenta:
- Source:
- Título: Abstracts
- Conference titles: Meeting of the Brazilian Society for Immunology
-
ABNT
OLIVEIRA, S I et al. Effect of WEB2170 in B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and CASPASE-3. 2006, Anais.. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo, 2006. . Acesso em: 10 jan. 2026. -
APA
Oliveira, S. I., Andrade, L. N. S., Pinheiro, M. C., Nonogaki, S., Chammas, R., & Jancar, S. (2006). Effect of WEB2170 in B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and CASPASE-3. In Abstracts. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo. -
NLM
Oliveira SI, Andrade LNS, Pinheiro MC, Nonogaki S, Chammas R, Jancar S. Effect of WEB2170 in B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and CASPASE-3. Abstracts. 2006 ;[citado 2026 jan. 10 ] -
Vancouver
Oliveira SI, Andrade LNS, Pinheiro MC, Nonogaki S, Chammas R, Jancar S. Effect of WEB2170 in B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and CASPASE-3. Abstracts. 2006 ;[citado 2026 jan. 10 ] - PAF receptor and tumor growth
- Effect of WEB2170 on B16F10 melanoma growth survival time and expression of galectin-3, CD34 and caspase-3
- Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy
- Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy
- Combined effects of dacabarzine and R715, an antagonist of the bradykinin receptor subtype I, impaired melanoma associated angiogenesis
- Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis
- Synthesis and preliminary assessment of 99m tc -HYNIC-Fab's (rituximab) for non-Hodgkin lymphoma diagnosis
- Guanosine promotes B16F10 melanoma cell differentiation through PKC–ERK 1/2 pathway
- O Instituto do Câncer do Estado de São Paulo, instituro especializado em Oncologia...[Prefácio]
- Introdução ao câncer
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
